- Oxford health tech spinout Ultromics has secured $55 million in Series C funding, led by Lightrock, L&G, and Allegis Capital, to scale its business and technology across the USA and other target markets.
- This funding will be used to accelerate Ultromics’ mission to transform heart disease detection and establish EchoGo®, its AI diagnostics platform, which enhances echocardiographic diagnosis and enables earlier diagnosis of tough-to-spot conditions.
- The company’s clinically proven technology was developed in collaboration with the Mayo Clinic in the USA and the UK’s National Health Service (NHS). It has received FDA approval and has been validated by leading scientific journals.
OXFORD, United Kingdom, 2025 — Ultromics, a pioneer in AI-driven cardiology diagnostics solutions, today announced it has raised $55 million through its Series C funding round. The funding round was co-led by L&G, Allegis Capital, and Lightrock. It also received continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Additionally, the University of Chicago Medicine and UPMC Enterprises, the innovation, commercialization and investment arm of UPMC (University of Pittsburgh Medical Center), both major US health systems, participated in the round.
Built on years of clinical study and analysis of hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, two of the most elusive forms of heart failure. Conventional solutions often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses. Up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or cardiac arrest occurs.
The company will use the proceeds of the round to expand across the US and other key markets to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac examinations. Ultromics is also expanding its product pipeline to include additional cardiac conditions, new distribution channels, and deeper partnerships with health systems and clinical leaders.
Ultromics addresses this diagnostic blind spot by using AI in its EchoGo® platform to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions, without requiring new hardware or disrupting clinical workflows. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under the USA’s Medicare program, making it scalable across hospitals, clinics, and health systems across the nation.
“The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it. By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses,” said Ross Upton, PhD, CEO and Founder, Ultromics. “We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”
Ultromics has already analysed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company’s latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions.
“Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies,” said Alastair Stewart, Head of Investments, Venture Capital, at L&G. “This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.”
With growing adoption and partnerships across flagship institutions, including University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the USA’s Midwest. The platform is designed to assist hospitals by reducing unnecessary tests, streamlining workflows, and enabling earlier initiation of treatment. This approach aims to enhance the effectiveness of medical interventions while also reducing costs.
“Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care,” said Umur Hursever, Partner at Lightrock. “Ultromics’ AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics’ mission and growing impact.”
Ultromics has rapidly expanded its platform capabilities and US market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics’ foundation for scaled adoption across USA hospitals.
“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret,” said Victor Westerlind, Managing Director at Allegis Capital. “What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.”
